Communiqués Spyre Therapeutics, Inc.

Actions

SYRE

US00773J2024

Recherche biotechnologique et médicale

Marché Fermé - Nasdaq 22:00:00 11/09/2026			Varia. 5j.	Varia. 1 janv.
90,60 ^USD	+2,13%		+3,84%	+176,56%

09/09	Transcript : Spyre Therapeutics, Inc. Presents at Citigroup?s Biopharma Back to School Summit 2026, Sep-09-2026 10:00 AM
08/09	Le SPY003 de Spyre Therapeutics atteint son critère d'évaluation principal en phase 2 dans la rectocolite hémorragique	MT

Communiqués

08/09	Spyre Announces Potential Best-in-Class SPY003 (anti-IL-23) Part A Induction Results from SKYLINE Trial, Completing Proof-of-Concept for All Three Components of its IBD Combinations	GL
04/09	Spyre Therapeutics Announces Grants of Inducement Awards	AQ
03/09	Spyre Therapeutics to Participate in Upcoming September Investor Conferences	GL
25/08	Spyre Therapeutics Announces Topline Results from the Rheumatoid Arthritis Sub-study of the SKYWAY Phase 2 Trial of SPY072	GL
10/08	Spyre Therapeutics Announces Launch of SPY772 Program and Initiation of Phase 2 SKYLIGHT Trial in Hidradenitis Suppurativa	GL
07/08	Spyre Therapeutics Announces Grants of Inducement Awards	AQ
04/08	Spyre Therapeutics: Q2 Earnings Snapshot	AQ
04/08	Spyre Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update	GL
02/07	Spyre Therapeutics Announces Grants of Inducement Awards	AQ
15/06	Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients	GL
15/06	Spyre Announces Potential Best-in-Class SPY002 (anti-TL1A) Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients	AQ
05/06	Spyre Therapeutics Announces Grants of Inducement Awards	AQ
03/06	Spyre Therapeutics Announces Completion of Enrollment in SKYWAY Basket Trial Evaluating SPY072 (anti-TL1A) in RA, PsA, and axSpA	GL
26/05	Spyre Therapeutics to Participate in Upcoming June Investor Conferences	GL
05/05	Spyre Therapeutics: Q1 Earnings Snapshot	AQ
05/05	Spyre Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update	GL
01/05	Spyre Therapeutics Announces Grants of Inducement Awards	AQ
16/04	Spyre Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $463.5 Million	GL
15/04	Spyre Therapeutics Announces Pricing of Upsized $403.0 Million Public Offering of Common Stock	GL
13/04	Spyre Therapeutics Announces Proposed Public Offering of its Common Stock	GL
13/04	Spyre Therapeutics : SKYLINE A SPY001 vFINAL	PU
13/04	Spyre Announces Potential Best-in-Class SPY001 Part A Induction Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients	GL
10/04	Spyre Therapeutics to Host Conference Call to Report SPY001 Part A Induction Topline Results from SKYLINE Trial in Moderate-to-Severe Ulcerative Colitis Patients on April 13, 2026	GL
03/04	Spyre Therapeutics Announces Grants of Inducement Awards	AQ
16/03	Spyre Announces Acceleration of Expected Topline Readout of SKYWAY Rheumatoid Arthritis Sub-study to Q3 2026	GL